

# Medicare Advantage Provider Bulletin



News and Information

May 15, 2025

## Enhanced Medical Drug Biosimilar Step Therapy Criteria Update

Effective July 1, 2025, Aspirus Health Plan Medicare Advantage will update the biosimilar step therapy criteria within medical drug policies to require a trial of a preferred biosimilar product when all medical necessity criteria are met. This includes, but is not limited to, an allergic reaction to a specific inactive ingredient in the preferred biologic or use for a diagnosis not approved for the preferred biosimilar product. The facility's unwillingness to order or stock the preferred product(s) will not be considered.

### Policy

Providers will find this policy in [Aspirus Health Plan's Medical Drug Policies](#) library on July 1, 2025.

Contact Aspirus Health Plan's Provider Assistance Center at 715.631.7412 or 1.855.931.4851 toll-free, Monday through Friday, 8 am – 5 pm with questions.

### Provider Bulletin

*Aspirus Health Plan has partnered with UCare, based out of Minnesota, as the administrator for our Medicare Advantage Plan.*

